Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DIRECTA PLUS PLC Board/Management Information 2020

Jul 28, 2020

7601_mang_2020-07-28_151be27c-86cc-4d7d-8278-b562ba3036ef.html

Board/Management Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 2198U

Directa Plus PLC

28 July 2020

28 July 2020

Directa Plus plc

("Directa Plus" or the "Company")

Appointment of Nominated Adviser and Joint Broker

Directa Plus plc (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, is pleased to announce that it has appointed Cenkos Securities plc as Nominated Adviser and Joint Broker with immediate effect.

For further information please visit http://www.directa-plus.com/ or contact:

Directa Plus plc

Giulio Cesareo, CEO

Marco Ferrari, CFO
Tel:  +39 02 36714458
Cenkos Securities plc (Nomad & Joint Broker)

Neil McDonald / Pete Lynch
Tel:  +44 131 220 6939
N+1 Singer (Joint Broker) Tel: +44 20 7496 3069
Mark Taylor
Tavistock (Financial PR and IR) Tel: +44 20 7920 3150
Simon Hudson / Edward Lee

About Directa Plus

Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product) and textiles (based on our G+ products).  In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products.  All our products are hypoallergenic, non-toxic and sustainably produced.

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

APPQDLFLBDLXBBZ